USP17L11
associated omics dataQ-omics provides the consensus-scored USP17L11 profile across patient tissues and cancer cell-line models. USP17L11 expression is associated with patient survival in 2 of 34 cancer types, with the highest sampling consensus in KIRC.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP17L11 — synthetic lethality, tumor antigen, and pembrolizumab response.
View premium →Survival associations
This table summarizes USP17L11 survival associations across molecular data types. USP17L11 RNA expression shows survival associations in the most cancer types (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP17L11 RNA expression–survival associations across cancer types. High USP17L11 expression shows unfavorable associations in KIRC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP17L11 RNA expression.
Cross-omics associations
This table shows molecular features associated with USP17L11 in patient tissues and cancer cell lines. In cancer cell lines, USP17L11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.